LIGAND PHARMACEUTICALS INC
About LIGAND PHARMACEUTICALS INC
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $268.1M
- Net income
- $124.5M
- Total assets
- $1.6B
- Market cap
- $4.7B
- Operating margin
- 15.3%
- Net margin
- 46.4%
Source: SEC EDGAR · updated Jun 8, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $268.1M
- Operating expenses
- $227.1M
- Operating income
- $41.0M
- Income tax
- $34.5M
- Net income
- $124.5M
- EPS (basic)
- $6.44
- EPS (diluted)
- $6.13
Balance sheet
- Total assets
- $1.6B
- Current assets
- $832.3M
- Total liabilities
- $543.4M
- Current liabilities
- $37.4M
- Shareholders’ equity
- $1.0B
Cash flow
- Operating cash flow
- $49.4M
- Investing cash flow
- -$377.3M
- Financing cash flow
- $428.2M
- Net cash flow
- $102.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $4.7B
- P/E ratio
- 38.8
- EPS (diluted)
- $6.13
- Shares outstanding
- 20.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 25, 1994
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $124.5M in FY2025.
- Revenue declined 3% from FY2021 to FY2025.
- Trading near its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 38.8.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review LIGAND PHARMACEUTICALS INC.
Write a review
News about LIGAND PHARMACEUTICALS INC
News & sentiment via Polygon.io
